Impact Factor
3.30
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.52
152 total citations
h5-index
21
h5 depth signal
Cited share
84.8%
39 of 46
Total citations
152
Citation footprint
Metric signal
2.17
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
175
China
70
United Kingdom
21
Greece
21
Germany
17
Citing Fields of Research
Cardiology
359
Diabetes
50
Lipids
43
Physiology
29
Hematology
20
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,406
Articles tracked across the journal lifetime
Indexed publication set
46
39 cited publications
Last 12 months
24
3.0 publications/month
Open access share
100.0%
24 OA publications in the last year
Leading citing country
United States
175 citing publications
Leading citing field
Cardiology
359 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v5n1, 2000-
v5n1, 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Broad Categories
Cardiology
Pharmacology
Vascular Diseases
Diabetes
Urology
MeSH Descriptors
Cardiovascular Agents
Cardiovascular Diseases
Cardiovascular System
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/10742484261495417
Open DOI
β3-Adrenergic Receptor Agonism Reduces Right Ventricular Systolic Pressure in a Preclinical Model of Heart Failure With Preserved Ejection Fraction-Associated Pulmonary Hypertension
Purpose: Pulmonary hypertension (PH) commonly complicates heart failure with preserved ejection fraction (HFpEF), driving morbidity and mortality, yet no therapies exist for HFpEF-PH. β3-adrenergic receptor (ADRB3) agonists may provide c...
02
DOI 10.1177/10742484261490639
Open DOI
Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study
Objective: To investigate adherence to four direct oral anticoagulants (DOACs) and its influencing factors in patients with non-valvular atrial fibrillation (NVAF), providing evidence for strategies to improve adherence. Methods: A retro...
03
DOI 10.1177/10742484261492865
Open DOI
Lipoprotein(a) After HORIZON: Causal Culprit, Risk Marker, or Unfulfilled Therapeutic Promise?
04
DOI 10.1177/10742484261483397
Open DOI
Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study
Background: Platelet reactivity varies after ST-segment-elevation myocardial infarction (STEMI). We evaluated serial platelet function-guided P2Y12 modulation after a 1-month ticagrelor run-in. Methods: At month 1, 114 patients were rand...
05
DOI 10.1177/10742484261476920
Open DOI
From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium
06
DOI 10.1177/10742484261468508
Open DOI
Targeting Aldosterone Biosynthesis in Uncontrolled and Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials of Lorundrostat and Baxdrostat.
BackgroundAldosterone excess contributes to uncontrolled and resistant hypertension, making aldosterone synthase inhibition a promising therapeutic strategy. Recent randomized trials have evaluated the selective aldosterone synthase inhi...
07
DOI 10.1177/10742484261459258
Open DOI
Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study
Background: Vericiguat improves outcomes in heart failure with reduced ejection fraction (HFrEF), but its vascular and hemodynamic effects remain unclear. We explored changes in flow-mediated dilation (FMD) and invasive hemodynamics afte...
08
DOI 10.1177/10742484261456161
Open DOI
Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study
Background: Cardiogenic shock remains a life-threatening condition with persistently high mortality. Norepinephrine and dopamine are commonly used vasoactive agents; however, comparative data on clinical outcomes remain limited. Methods:...
09
DOI 10.1177/10742484261457268
Open DOI
ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy
Background: The ABCD-GENE (Age, Body Mass Index, Chronic Kidney Disease, Diabetes Mellitus, and Genotyping) score is a tool used to identify increased thrombotic risk in clopidogrel-treated patients. We evaluated the association between ...
10
DOI 10.1177/10742484261452727
Open DOI
Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus
Background: Platelet hyperactivity contributes to elevated cardiovascular risk in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, exert beneficial effects on platelet function and card...
Bibliographical & Catalog Notes
Title from cover.
Imprint varies.
Also issued online.